Invus Group
Invus Group specializing in buyouts, buyins, turnaround, longer-term public equity investments.
Business Model:
Revenue: $8M
Employees: 11-50
Detailed Invus Group Information
Geographic Data
Address: 750 Lexington Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Metrics
3,647,186Website Global Rank
3,607Website Monthly Traffic
Twitter Followers
Description
Invus Group specializing in buyouts, buyins, turnaround, longer-term public equity investments.
Contact Phone:
+12123711717
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 3/2016 | The Curious AI Company | Convertible Note | 1.3M |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 9/2020 | PrognomiQ | Venture Round | 0 |
| 1/2018 | Celtaxsys | Series E | - |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 9/2018 | KSQ Therapeutics | Series C | 80M |
| 4/2012 | Zero Motorcycles | Venture Round | 9M |
| 4/2022 | Zero Motorcycles | Funding Round | 86.6M |
| 1/2012 | Zero Motorcycles | Venture Round | 2.2M |
| 3/2011 | Zero Motorcycles | Venture Round | 17M |
| 10/2012 | Zero Motorcycles | Venture Round | 6M |
| 12/2020 | Yumanity Therapeutics | Venture Round | 0 |
| 7/2019 | Seer | Series C | 17.5M |
| 12/2010 | Abound Solar | Private Equity Round | 110M |
| 3/2023 | Noema Pharma | Series B | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 4/2021 | Wiloki | Venture Round | 1.2M |
| 1/2022 | Leyden Labs | Series B | 140M |
| 8/2021 | Laronde | Series B | 440M |
| 6/2019 | Tea Monsters | Angel Round | 3.3M |
| 7/2021 | Ring Therapeutics | Series B | 117M |
| 5/2001 | Netcontinuum | Series B | 26M |
| 5/2009 | SDC Materials,Inc. | Series B | 14M |
| 7/2012 | Airties | Series B | - |
| 7/2022 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 4/2008 | Zero Motorcycles | Venture Round | 5.1M |
| 10/2019 | Thrive Market | Convertible Note | 20M |
| 9/2019 | Inotrem | Series B | 43.1M |
| 1/2021 | FogPharma | Series C | 107M |
| 3/2017 | Cava Group | Series C | 30M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 4/2021 | Cava Group | Series F | 0 |
| 7/2020 | Seer | Series D | 55M |
| 3/2018 | Future Finance | Series C | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 9/2012 | ZenRobotics | Series A | 17M |
| 12/2021 | Jumbotail | Series C | 84.9M |
| 1/2021 | Valo Health | Series B | 190M |
| 1/2017 | PatientsLikeMe | Venture Round | 0 |
| 9/2016 | Arcus Biosciences | Series B | 70M |
| 7/2017 | Rebound Therapeutics | Series B | 0 |
| 12/2020 | Locanabio | Series B | 0 |
| 4/2021 | Repertoire Immune Medicines | Series B | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 3/2000 | SNAZ.com | Series A | 0 |
| 4/2020 | Erasca | Series B | 0 |
| 2/2018 | Generation Bio | Series B | 100M |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 3/2018 | UNITY Biotechnology | Series C | 55M |
| 8/2017 | UNITY Biotechnology | Series B | 35M |
| 1/2018 | Scholar Rock | Series C | 47M |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 10/2022 | Neumora Therapeutics | Series B | 0 |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 2/2007 | PatientsLikeMe | Series A | 0 |
| 6/2022 | Scholar Rock | Post-IPO Equity | 0 |
| 3/2020 | ElevateBio | Series B | 170M |
| 1/2021 | Ikena Oncology | Series B | 0 |
| 1/2017 | Dropee | Pre Seed Round | 66.9k |
| 7/2020 | Imvax | Series C | 0 |
| 12/2016 | FlatFrog Laboratories | Venture Round | 6.4M |
| 2/2015 | Jahia | Venture Round | 22.5M |
| 2/2021 | Evox Therapeutics | Series C | 96.7M |
| 11/2015 | TigerConnect | Series C | 0 |
| 12/2020 | Olive | Series A | - |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 2/2019 | Hookipa Pharma | Series D | 37.4M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 5/2019 | Schrödinger | Series E | 25M |
| 6/2022 | HappyVore | Venture Round | 36.9M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 5/2021 | Flare Therapeutics | Series A | 82M |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 3/2021 | Asher Bio | Series A | 0 |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 3/2020 | Health Data Analytics Institute | Venture Round | 16M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2008 | Abound Solar | Venture Round | 104M |
| 11/2020 | Ambrx | Private Equity Round | 200M |
| 3/2016 | Future Finance | Series B | 29.2M |
| 3/2022 | PrognomiQ | Venture Round | 0 |
| 1/2010 | FlatFrog Laboratories | Venture Round | 0 |
| 1/2014 | FlatFrog Laboratories | Venture Round | 10M |
| 6/2012 | FlatFrog Laboratories | Venture Round | 25.4M |
| 7/2019 | Kronos Bio | Series A | 105M |
| 10/2022 | Recursion Pharmaceuticals | Post-IPO Equity | 150M |
| 3/2022 | LifeMine Therapeutics | Series C | 0 |
| 2/2023 | Hemab | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 12/2018 | Seer | Series B | 36M |
| 1/2015 | Moderna Therapeutics | Series E | 0 |
| 9/2017 | Bizagi | Private Equity Round | 48M |
| 5/2023 | Convergent Therapeutics | Series A | 0 |
| 12/2021 | ezCater | Series D | 0 |
| 3/2021 | Omega Therapeutics | Series C | 126M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 1/2020 | Generation Bio | Series C | 110M |
| 12/2020 | Amount | Series C | 86M |
| 3/2000 | E-Color | Venture Round | 9M |
| 2/2019 | Oyster Point Pharmaceuticals | Series B | 0 |
| 6/2022 | Senti Biosciences | Post-IPO Equity | 0 |
| 10/2000 | E-Color | Venture Round | 24.6M |
| 12/2019 | Seer | Series D | 55M |
| 8/2003 | Renovis | Series E | 45M |
| 7/2015 | Marlette Funding | Venture Round | 75M |
| 1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 7/2022 | Vascular Dynamics | Venture Round | 0 |
| 2/2021 | Sagimet Biosciences | Venture Round | 0 |
| 3/2020 | Element Science | Series C | 145.6M |
| 5/2021 | Amount | Series D | 99M |
| 6/2018 | Metacrine | Series C | 65M |
| 9/2011 | Opera Solutions | Private Equity Round | 84M |
| 1/2022 | Septerna | Series A | 100M |
| 5/2019 | Thrive Earlier Detection | Series A | 110M |
| 11/2014 | AposHealth | Venture Round | 15M |
| 5/2019 | AlloVir | Series B | 120M |
| 3/2021 | EGenesis | Series C | 0 |
| 4/2012 | MarkaVIP | Series B | 10M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 6/2021 | Lyndra Therapeutics | Series C | 0 |
| 10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
| 9/2018 | Morphic Therapeutic | Series B | 0 |
| 5/2020 | SQZ Biotech | Series D | 0 |
| 12/2020 | Noema Pharma | Series A | 60M |
| 6/2021 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
| 6/2019 | Booster | Series C | 56M |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 3/2021 | ElevateBio | Series C | 525M |
| 5/2023 | ElevateBio | Series D | 0 |
| 7/2022 | AlloVir | Post-IPO Equity | 0 |
| 6/2021 | Abata Therapeutics | Series A | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 5/2018 | PACT Pharma | Series B | 95M |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 3/2021 | Caribou Biosciences | Series C | 115M |
| 2/2019 | Lyndra Therapeutics | Series B | 0 |
| 9/2022 | Pretzel Therapeutics | Series A | 0 |
| 8/2019 | ORIC Pharmaceuticals | Series D | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 3/2023 | Bicara Therapeutics | Series B | 0 |
| 2/2018 | Zenflow | Series A | 31.4M |
| 9/2019 | Mission Lane | Series A | 0 |
| 9/2017 | The Curious AI Company | Venture Round | 3.7M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 8/2018 | SQZ Biotech | Series C | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 3/2023 | Flare Therapeutics | Series B | 0 |
| 3/2005 | Elixir Medical | Series A | 5.3M |
| 3/2010 | Lexicon Pharmaceuticals | Post-IPO Equity | 75M |
| 1/2010 | Zero Motorcycles | Series A | 8M |
| 3/2017 | KNIME | Series A | 21.5M |
| 4/2022 | Onxeo | Post-IPO Equity | 8.7M |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 1/2004 | Standard BioTools | Series D | 21M |
| 3/2020 | Enwise | Venture Round | 20M |
| 1/2018 | Enwise | Venture Round | - |
| 12/2016 | Enwise | Seed Round | - |
| 3/2019 | Escale | Series C | 22.6M |
| 5/2021 | Escale | Series C | 27.5M |
| 1/2018 | BioNTech | Series A | 270M |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 10/2015 | The Curious AI Company | Seed Round | 895.3k |
| 5/2021 | Engine Biosciences | Series A | 0 |
| 12/2011 | MarkaVIP | Series A | 5M |
| 2/2016 | Snagajob | Series D | 0 |
| 2/2020 | Viseon | Series B | 18M |
| 10/2020 | TigerConnect | Series D | 0 |
| 9/2017 | Viseon | Series A | 5M |
| 9/2015 | Cava Group | Series B | 45M |
| 8/2022 | Sironax | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 6/2022 | HappyVore | Funding Round | 0 |
| 12/2019 | Triplet Therapeutics | Series A | 49M |
| 6/2018 | Kaleido | Series C | 101M |
| 3/2000 | IAM com | Venture Round | 35.7M |
| 5/2019 | Foghorn Therapeutics | Venture Round | 61M |
| 6/2016 | Thrive Market | Series B | 111M |
| 10/2005 | Netcontinuum | Venture Round | 15M |
| 7/2019 | BioNTech | Series B | 0 |
| 8/2022 | Sironax | Series B | 0 |
| 7/2022 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 7/2022 | AlloVir | Post-IPO Equity | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 7/2022 | Vascular Dynamics | Venture Round | 0 |
| 6/2022 | Scholar Rock | Post-IPO Equity | 0 |
| 6/2022 | HappyVore | Funding Round | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 6/2022 | Senti Biosciences | Post-IPO Equity | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 6/2016 | Ashley Stewart |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
